NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Friday,Benzinga reports.
NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s loss per share is pinned at 20 cents. In the absence of a marketed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback